| Clinical data | |
|---|---|
| Other names | AA-560; N-(2-Chloromethyl-2-hydroxypropionyl)-3,4,5-trichloroaniline |
| Routes of administration | By mouth[1] |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H10Cl3NO2 |
| Molar mass | 282.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AA560 is anorally activenonsteroidal antiandrogen (NSAA) that was developed inJapan and was first described in the literature in 1977 but was never marketed.[1][2][3] It is ananilidederivative andanalogue of the NSAAflutamide, and shows greaterin vivo antiandrogenicpotency than does flutamide.[1][2] Similarly to flutamide, AA560 is aselectiveantagonist of theandrogen receptor (AR) and consequently showsprogonadotropic effects by increasing levels ofgonadotropins andtestosterone via disinhibition of thehypothalamic-pituitary-gonadal axis.[1][2][4]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |